IRCT20221101056361N1 IRCT 2023-04-08 Shahre-kord University of Medical Sciences Effect of Metformin and Megestrol in treatment of Endometrial hyperplasia Comparative Effect of Using Megestrol Alone and its Combination with Metformin in the Treatment of Endometrial Hyperplasia without Atypia 2022-03-20 anticipated 60 Complete https://irct.ir/trial/67428 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The researcher assigns a number to the patients using the random allocation rule method and then puts the cards on which the patient's number is written in an envelope in a shuffle. In this method, according to the sample volume, two colors of cards (red and blue or A and B stickers) are poured into the envelope with the same number equal to the total volume of the sample. Then the eligible people entered into the study will randomly take out one of the cards from the envelope and according to the definition of the researcher, if they take the red or A card, they will enter the intervention group, and if they take the blue or B card, they will enter the control group, Blinding description: The method of blinding is that the patients of the intervention and control groups are unaware of the type of drug being used, and metformin and placebo drugs will be prepared in the form of tablets with the same shape and size. Considering the type of study that is one-sided blind, after randomization And entering the groups, patients in the control group will be given megestrol and placebo, and the patients in the intervention group will be given metformin and megestrol. 3 Endometrial hyperplasia. Intervention 1: Intervention group: 30 people with endometrial hyperplasia will use 40 mg megestrol and placebo from Ectororco for 14 days per month (14 days after the start of period) for 3 months. Intervention 2: Intervention group: 30 people with endometrial hyperplasia who use 1000 mg of metformin for 14 days per month for 3 months in addition to 40 mg of megestrol. Yes - There is a plan to make this available What will be shared: To share the data and documents of this research, only the information related to the main outcome will be shared. Also, files that can be published and do not violate people's privacy are published When: The access period will start 6 months after the results are published To whom: Our data is only available to researchers working in scientific and academic institutions Conditions: If there are conditions, all our data will be shared except personal information of people. The use of our data is only allowed for similar research by other researchers. All those who work in scientific and academic centers and decide do similar research can access our data. Where to obtain: In order to receive information, all eligible people can collect data by referring to the person responsible for the project. E-mail:paridokht.nourian@gmail.com ,09132326474 How to obtain: To receive information after sending the request, the requests will be reviewed within 10 days, and if the conditions are met, it will be sent to the provided email within 30 days. Comments: